ABSTRACT
As SARS-CoV-2 continues to evolve, mutations arise that will allow the virus to evade immune defenses and therapeutics. Assays that can identify these mutations can be used to guide personalized patient treatment plans. Digital PCR (dPCR) is a fast and reliable complement to whole genome sequencing that can be used to discriminate single nucleotide polymorphisms (SNPs) in template molecules. Here, we developed a panel of SARS-CoV-2 dPCR assays and demonstrate its applications for typing variant lineages and therapeutic monoclonal antibody resistance. We designed multiplexed dPCR assays for SNPs located at residue 3395 in the orf1ab gene and residue 143 of the spike gene that differentiate the Delta, Omicron BA.1, and Omicron BA.2 lineages. We demonstrate their validity on 596 clinical saliva specimens that were sequence-verified using Illumina whole genome sequencing. Next, we developed dPCR assays for spike mutations R346T, K444T, N460K, F486V, and F486S mutations that are associated with host immune evasion and reduced therapeutic monoclonal antibody efficacy. We demonstrate that these assays can be run individually or multiplexed to detect the presence of up to 4 SNPs in a single assay. We validate these dPCR assays on 81 clinical saliva SARS-CoV-2 positive specimens from Omicron subvariants BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1, BQ.1.1, and XBB. Thus, dPCR could serve as a useful tool to determine if clinical specimens contain therapeutically relevant mutations and inform patient treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Arizona Department of Health Services (CTR053916), the Centers for Disease Control and Prevention (CDC BAA 75D30121C11084) and Tohono OOdham Nation (2020-01 ASU).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Arizona State University Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Genome sequences have been deposited to the GISAID repository. Scripts for data curation can be found on the Lim lab GitHub (https://github.com/ASU-Lim-Lab/Absolute-Q).
ABBREVIATIONS
- (SARS-CoV-2)
- Severe acute respiratory syndrome coronavirus 2
- (COVID-19)
- Coronavirus Disease 2019
- (RT-dPCR)
- Reverse transcription-digital polymerase chain reaction
- (VOC)
- Variant of concern